Avance Clinical Welcomes Kelly Yang As Associate Director, Operations Taiwan
Avance Clinical, a leading global contract research organization (CRO) specializing in advanced clinical research solutions for biotechs, is excited to announce the appointment of Kelly Yang as Associate Director, Operations Taiwan. Kelly brings over 15 years of experience in the pharmaceutical and clinical research industries, making her a valuable addition to Avance Clinical’s growing team.
Kelly’s extensive background spans clinical operations, project management, and strategic leadership across both the pharmaceutical and CRO sectors, where she has excelled in roles such as Project Director, Senior Project Leader, and Feasibility & Strategy Leader.
Prior to joining Avance Clinical, Kelly held leadership positions at other large CROs, where she managed complex projects and contributed to operational success.
“Avance Clinical’s commitment to supporting international biotechs and patients, particularly with its mission to expand into Asia, drew me to this new role,” said Kelly Yang. “I am excited to be a part of Avance Clinical’s mission to grow its presence in Taiwan and to help drive the operations in this key region. With my experience on both the pharmaceutical and CRO sides, and the incredible support of the Avance Clinical team, I look forward to the exciting journey ahead.”
Kelly holds a Bachelor of Science degree from Taiwan’s FU-JEN University and a Master of Science from the Graduate Institute of Immunology at National Taiwan University. Her scientific background, coupled with her operational expertise, positions her to lead Avance Clinical’s Taiwan operations with a focus on key opinion leader (KOL) and site engagement, clinical operations, project management, and business development support.
In her new role, Kelly will oversee the development of a high-performance local operations team, aimed at building a robust Avance Clinical Site Network in Taiwan. This network will offer sponsors faster and higher-quality trial outcomes, providing competitive timelines and reduced costs. “I’m excited to contribute to bringing more innovative drug trials to Taiwan, benefiting patients and increasing exposure to Taiwan’s clinical trial environment,” Kelly added.
“We are thrilled to welcome Kelly to Avance Clinical,” said Yvonne Lungershausen, CEO of Avance Clinical. “Her diverse experience in both the pharmaceutical industry and the CRO space, along with her leadership in project management, makes her a perfect fit to lead our operations in Taiwan. We are confident that her expertise will help us continue to grow our presence in Asia and deliver outstanding clinical trial outcomes for our sponsors.”
Joe Taouk, Vice President, Global Project Delivery said; “Kelly is a key addition to Avance Clinical’s ongoing strategic expansion across Asia, and the Taiwan operations, led by Kelly, play a critical role in enhancing the company’s position as a global CRO with a strong focus on Oncology and CNS clinical trials—two therapeutic areas with high demand in Taiwan,” he said.
Jessica Han, Director, Asian Operations added; “Kelly’s expertise in project management, clinical operations, and client engagement brings vital strength to our Taiwan team. Her commitment to delivering outstanding results will be instrumental as we advance our efforts in Taiwan, supporting our clients with high-quality outcomes and furthering Avance Clinical’s impact in this important market,” she said.
Avance Clinical’s use of advanced technologies, such as Veeva Vault and Medidata, and its ability to offer customized solutions tailored to biotech clients, will be key drivers of success in Taiwan. Kelly’s appointment reinforces Avance Clinical’s commitment to its strategy to expand into Asia, with a local footprint and workforce.